New malaria vaccine tested in african women to protect future pregnancies
NCT ID NCT06080243
Summary
This study is testing a malaria vaccine called R21/Matrix-M1 in healthy women in Mali who are of childbearing age and plan to become pregnant. The goal is to see if the vaccine is safe, how well the immune system responds to it, and if it protects against malaria infection. Researchers will compare different dosing schedules and follow participants, including any who become pregnant, for two years to monitor safety and check for malaria.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY WOMEN OF CHILD BEARING POTENTIAL are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Koumantou Study Clinic
Bougouni, Sikasso, Mali
Conditions
Explore the condition pages connected to this study.